Artificial Intelligence for New Drug Design
Courtesy of Iktos
Iktos Develops a Technology Platform for Deep Learning-Based de novo Drug Development
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.
Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, France-based start-up Iktos is developing a proprietary AI technology for ligand and structure-based de novo drug design, focusing on multi parametric optimization (MPO). Yann Gaston-Mathé, co-founder and CEO of Iktos, explains the company’s technologies and provides an outlook on the further development of the company.
-
Most popular related searches
Customer comments
No comments were found for Artificial Intelligence for New Drug Design. Be the first to comment!